12 Month Price Forecast For CLPT
Distance to CLPT Price Forecasts
CLPT Price Momentum
🤔 Considering ClearPoint Neuro (CLPT)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 10:02 AM UTC
CLPT Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, CLPT has a consensus that is bullish. The median price target is $17.00, with forecasts ranging from $15.00 to $17.00. Currently, there are 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CLPT currently trading at $16.40, the median price forecast suggests a 3.7% upside. The most optimistic forecast comes from at , projecting a 3.7% upside, while Frank Takkinen at Lake Street provides the most conservative target, suggesting a -8.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLPT Analyst Consensus
CLPT Price Target Range
Latest CLPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 27, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $15.00 |
| Mar 13, 2024 | Stifel | Mathew Blackman | Buy | Reiterates | $9.00 |
| Oct 24, 2023 | Stifel | Mathew Blackman | Buy | Initiates | $8.00 |
| Aug 9, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $15.00 |
| Feb 16, 2023 | B. Riley Securities | Neil Chatterji | Buy | Reinstates | $14.00 |
| Apr 5, 2022 | B. Riley Securities | Marc Wiesenberger | Buy | Reinstates | $15.00 |
| Mar 18, 2021 | Lake Street | Frank Takkinen | Buy | Initiates | $32.00 |
| Jul 17, 2020 | B. Riley Securities | Buy | Initiates | $0.00 |
ClearPoint Neuro Inc (CLPT) Financial Data
ClearPoint Neuro Inc has a market capitalization of $460.11M with a P/E ratio of -18.2x. The company generates $30.43M in trailing twelve-month revenue with a -59.6% profit margin.
Revenue growth is +41.0% quarter-over-quarter, while maintaining an operating margin of -63.7% and return on equity of -68.4%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
ClearPoint Neuro Inc (CLPT) Company Overview
About ClearPoint Neuro Inc
Develops minimally invasive brain surgical devices.
The company makes money by developing and commercializing advanced medical devices that facilitate minimally invasive surgical procedures guided by MRI. Their flagship product, the ClearPoint system, enables the precise insertion of devices such as deep brain stimulation electrodes and biopsy needles, generating revenue through sales, licensing agreements, and collaborations with prominent medical institutions and companies.
ClearPoint Neuro was incorporated in 1998 and is based in Solana Beach, California. The company has established several strategic partnerships and licensing agreements with notable organizations like Koninklijke Philips N.V. and UCB Biopharma SRL, which may enhance its product offerings and market reach.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
107
CEO
Mr. Joseph Michael Burnett
Country
United States
IPO Year
2012
Website
www.clearpointneuro.comClearPoint Neuro Inc (CLPT) Latest News & Analysis
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
29 days agoClearPoint Neuro's SmartFlow Neuro Cannula received FDA marketing authorization for delivering PTC Therapeutics' gene therapy KEBILIDI™ for AADC deficiency, marking a significant advancement in treatment options.
FDA approval of the SmartFlow Neuro Cannula opens new revenue streams for ClearPoint Neuro and enhances the market potential for PTC Therapeutics' gene therapy, impacting investor outlook.
ClearPoint Neuro: Near-Term Volatility Is No Concern
1 month agoClearPoint Neuro showed strong YoY growth in Q3 but faced a negative stock reaction, likely due to high valuation and weak sequential growth. Margins are improving, and cash burn is minimal.
ClearPoint Neuro's strong YoY growth contrasts with negative stock reaction due to high valuation and weak sequential growth, signaling potential volatility ahead despite improving margins and low cash burn.
ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript
1 month agoClearPoint Neuro, Inc. (NASDAQ:CLPT) will host its Q3 2024 earnings conference call on November 7, 2024, at 4:30 PM ET, featuring CEO Joe Burnett and CFO Danilo D'Alessandro.
ClearPoint Neuro's Q3 earnings call will provide insights into financial performance and strategic direction, impacting stock valuation and investor sentiment.
ClearPoint Neuro Reports Third Quarter 2024 Results
1 month agoClearPoint Neuro reported Q3 2024 revenue of $8.1M, up 41% YoY. Cash burn decreased to $1.2M. No debt remains, with cash reserves at $21.6M. Growth driven by new global centers and product sales.
Record revenue growth and reduced cash burn signal strong operational efficiency and financial health. The absence of debt enhances stability, making the company an attractive investment opportunity.
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Tops Revenue Estimates
1 month agoClearPoint Neuro, Inc. (CLPT) reported a quarterly loss of $0.18 per share, slightly worse than the expected loss of $0.17, improving from a loss of $0.20 per share a year earlier.
ClearPoint Neuro's larger-than-expected loss signals ongoing financial challenges, potentially impacting investor confidence and stock performance. Year-over-year improvement may provide some reassurance.
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024
1 month agoClearPoint Neuro, Inc. (NASDAQ: CLPT) announced its CEO Joe Burnett was featured on Bloomberg Intelligence's Vanguards of Healthcare Podcast and is participating in multiple investor conferences.
ClearPoint Neuro's CEO's appearance on a major platform like Bloomberg can enhance visibility, potentially attract investors, and influence stock performance through increased interest in the company's innovations.
Frequently Asked Questions About CLPT Stock
What is ClearPoint Neuro Inc's (CLPT) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, ClearPoint Neuro Inc (CLPT) has a median price target of $17.00. The highest price target is $17.00 and the lowest is $15.00.
Is CLPT stock a good investment in 2025?
According to current analyst ratings, CLPT has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CLPT stock?
Wall Street analysts predict CLPT stock could reach $17.00 in the next 12 months. This represents a 3.7% increase from the current price of $16.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ClearPoint Neuro Inc's business model?
The company makes money by developing and commercializing advanced medical devices that facilitate minimally invasive surgical procedures guided by MRI. Their flagship product, the ClearPoint system, enables the precise insertion of devices such as deep brain stimulation electrodes and biopsy needles, generating revenue through sales, licensing agreements, and collaborations with prominent medical institutions and companies.
What is the highest forecasted price for CLPT ClearPoint Neuro Inc?
The highest price target for CLPT is $17.00 from at , which represents a 3.7% increase from the current price of $16.40.
What is the lowest forecasted price for CLPT ClearPoint Neuro Inc?
The lowest price target for CLPT is $15.00 from Frank Takkinen at Lake Street, which represents a -8.5% decrease from the current price of $16.40.
What is the overall CLPT consensus from analysts for ClearPoint Neuro Inc?
The overall analyst consensus for CLPT is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are CLPT stock price projections?
Stock price projections, including those for ClearPoint Neuro Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
